MYQORZO shows strong early sales and market expansion potential for Cytokinetics in HCM treatment.

Cytokinetics' drug MYQORZO is gaining rapid market access with over 30% new-to-brand share and strong prescriber adoption, indicating solid commercial momentum beyond initial revenue reports. Clinical trials MAPLE-HCM and ACACIA-HCM suggest MYQORZO could be used earlier in treatment and expand its market to include non-obstructive hypertrophic cardiomyopathy, potentially doubling its addressable market. The company has $1.9 billion in liquidity to support aggressive growth, though investors should watch for risks related to high selling expenses, regulatory challenges, and intellectual property as the drug scales.